Sex differences in cardiovascular–kidney–metabolic risk factors associated with degenerative valvular heart disease - Takeaways - MDSpire

Sex differences in cardiovascular–kidney–metabolic risk factors associated with degenerative valvular heart disease

  • By

  • Cheng Yang

  • Ziang Li

  • Yonggang Sui

  • Tianxin Long

  • Sijing Cheng

  • Xinli Guo

  • Chengqing Jiang

  • Haowen Ma

  • Haiyan Xu

  • Jie Qian

  • Yongjian Wu

  • February 12, 2025

  • 0 min

Share

  • 1

    The study analyzed sex differences in cardiovascular–kidney–metabolic risk factors related to degenerative valvular heart disease in 436,184 UK Biobank participants.

  • 2

    Hypertension was identified as the largest attributable risk factor for incident valvular heart disease in both men and women.

  • 3

    Women exhibited higher risks of specific valvular heart disease subtypes associated with obesity, chronic kidney disease, hypertension, and hypertriglyceridaemia.

  • 4

    The study emphasizes the need for tailored prevention strategies based on gender to improve outcomes in degenerative valvular heart disease.

  • 5

    Despite the increasing incidence of degenerative valvular heart disease, effective preventive interventions remain largely unavailable.

Original Source(s)

Sex differences in cardiovascular–kidney–metabolic risk factors associated with degenerative valvular heart disease

  • by Cheng Yang, Ziang Li, Yonggang Sui, Tianxin Long, Sijing Cheng, Xinli Guo, Chengqing Jiang, Haowen Ma, Haiyan Xu, Jie Qian, Yongjian Wu

  • February 12, 2025

Related Content

Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is associated with cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes

Retinal Age as Disease Biomarker

Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

  • May 27, 2026

  • 3 min
Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.